218 related articles for article (PubMed ID: 9372045)
1. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors.
Ozer H
Curr Opin Hematol; 1996 Jan; 3(1):3-10. PubMed ID: 9372045
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
3. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
4. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
Liang DC
Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
[TBL] [Abstract][Full Text] [Related]
5. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
Gómez Raposo C; Pinto Marín A; González Barón M
Clin Transl Oncol; 2006 Oct; 8(10):729-34. PubMed ID: 17074671
[TBL] [Abstract][Full Text] [Related]
6. Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia.
Freyer G; Ligneau B; Trillet-Lenoir V
Int J Antimicrob Agents; 1998 Apr; 10(1):3-9. PubMed ID: 9624538
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
Johnston EM; Crawford J
Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
9. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
10. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
11. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
12. Myeloid growth factors.
Crawford J; Armitage J; Balducci L; Bennett C; Blayney DW; Cataland SR; Dale DC; Demetri GD; Erba HP; Foran J; Freifeld AG; Goemann M; Heaney ML; Htoy S; Hudock S; Kloth DD; Kuter DJ; Lyman GH; Michaud LB; Miyata SC; Tallman MS; Vadhan-Raj S; Westervelt P; Wong MK;
J Natl Compr Canc Netw; 2009 Jan; 7(1):64-83. PubMed ID: 19176207
[No Abstract] [Full Text] [Related]
13. Hematopoietic growth factors for chemotherapy-induced neutropenia.
Yalçin S
Cancer Invest; 1999; 17(7):555-6. PubMed ID: 10518202
[No Abstract] [Full Text] [Related]
14. [Recommendation for using granulocyte and granulocyte-macrophage growth factor during anti-cancer therapy in children].
Balwierz W; Moryl-Bujakowska A; Balwierz A; Pawińska K
Przegl Lek; 2006; 63(1):1-6. PubMed ID: 16892890
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
[TBL] [Abstract][Full Text] [Related]
16. The role of myelopoietic growth factors in managing cancer in the elderly.
Balducci L; Carreca I
Drugs; 2002; 62 Suppl 1():47-63. PubMed ID: 12479594
[TBL] [Abstract][Full Text] [Related]
17. Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia.
Ottmann OG; Bug G; Krauter J
Semin Hematol; 2007 Jul; 44(3):183-92. PubMed ID: 17631182
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
19. [G-CSF in oncology].
Viret F; Gonçalves A; Tarpin C; Chabannon C; Viens P
Bull Cancer; 2006 May; 93(5):463-71. PubMed ID: 16777624
[TBL] [Abstract][Full Text] [Related]
20. Clinical applications of colony-stimulating factors: a historical perspective.
Sylvester RK
Am J Health Syst Pharm; 2002 Apr; 59(7 Suppl 2):S6-12. PubMed ID: 11944613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
